Reports Q4 revenue $274.5M, consensus $376.67M. "Globus Medical was founded twenty years ago with a small group of talented engineers who had a vision of improving care for patients with musculoskeletal disease," said Dan Scavilla, president and CEO. "I’m proud to announce that in 2022, Globus Medical exceeded $1 billion in net sales. The journey from startup to $1 billion in sales is certainly worthy of note and particularly so at this milestone anniversary of the company’s founding. The fourth quarter of 2022 was a record-setting quarter, with record-breaking total sales, U.S. Spine sales, and Enabling Technologies sales. Our future continues to look bright as we improve the lives of patients, surgeons, employees and shareholders by working to further achieve our vision. We plan to build on our legacy of product innovation, superior customer services, and operational execution this year and in the future as we continue to help patients with musculoskeletal disease."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GMED:
- Globus Medical Reports Fourth Quarter and Full Year 2022 Results
- Globus Medical downgraded to Underperform from Buy at BofA
- Globus Medical downgraded to Equal Weight from Overweight at Wells Fargo
- NuVasive downgraded to Equal Weight from Overweight at Wells Fargo
- Needham downgrades Globus on ‘meaningful’ integration risks
